Home › Forums › Main Forum › Media & News › HCV New Drugs Blogspot
- This topic has 175 replies, 27 voices, and was last updated 8 years ago by mgalbrai.
-
AuthorPosts
-
22 February 2016 at 6:10 pm #12452
From the weekend:
http://hepatitiscnewdrugs.blogspot.com/2016/02/watch-cost-of-curing-hepatitis-c-bbc.html
http://hepatitiscnewdrugs.blogspot.com/2016/02/second-state-sued-over-hepatitis-c.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2423 February 2016 at 8:29 pm #12529New Screening and treatment criteria from WHO:
http://hepatitiscnewdrugs.blogspot.com/2016/02/new-recommendations-in-updated-who.html
Thousands recalled for hepatitis C test after NHS worker’s diagnosis:
http://hepatitiscnewdrugs.blogspot.com/2016/02/thousands-recalled-for-hepatitis-c-test.htmlBristol-Myers Squibb (NYSE:BMY) Presents Data on All-Oral Hepatitis C Regimen:
http://hepatitiscnewdrugs.blogspot.com/2016/02/bristol-myers-squibb-nysebmy-presents.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2424 February 2016 at 3:12 am #12540That last article is curious considering BMS withdrew application for approval of asuneprevir (in combination with daclatavir) in Oct 2014 Because –
In clinical trials, BMS’s combination, on the other hand, cured just 82 percent to 90 percent of those with genotype 1b after 24 weeks.
Source – https://www.hepmag.com/article/asunaprevir-end-26284-925493039
I wonder what changed, as they are reporting higher SVR rates in this trial?
M 61yo HCV+ ~ 30 yrs Gt1a F2 VL 223,000 ALT 54 AST 42 Tx start Sof/Dac 17Dec15.
SVR4 at 7Apr16 ALT 22 AST 22
SVR12 at 9Jun16 ALT 23 AST 25
Melbourne, Australia24 February 2016 at 7:11 pm #12624Re Cirrhosis:
2/24/16http://hepatitiscnewdrugs.blogspot.com/2016/02/alimentary-pharmacology-therapeutics.html
Re Zepatier:
http://hepatitiscnewdrugs.blogspot.com/2016/02/evidence-review-of-zepatier-vs-harvoni.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2425 February 2016 at 3:55 am #12638sonix wrote:That last article is curious considering BMS withdrew application for approval of asuneprevir (in combination with daclatavir) in Oct 2014 Because –
In clinical trials, BMS’s combination, on the other hand, cured just 82 percent to 90 percent of those with genotype 1b after 24 weeks.
Source – https://www.hepmag.com/article/asunaprevir-end-26284-925493039
I wonder what changed, as they are reporting higher SVR rates in this trial?
Looks like the 2014 report relates to earlier trials for approval for use in US so probably consisted mostly of western patient profile whereas these latest late stage trial results are for an all Chinese patient profile. This differing result is possibly to be expected as various racial groupings show differing responses to the old interferon treatments and also susceptibility to fibrosis/cirrhosis.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
26 February 2016 at 9:01 pm #12757Lots of good reading here:
Indian Patent Challenge:
http://hepatitiscnewdrugs.blogspot.com/2016/02/access-patent-challenge-hearing-on.html
ABBVIE RECEIVES CHMP POSITIVE OPINION FOR VIEKIRAX® (OMBITASVIR/PARITAPREVIR/RITONAVIR TABLETS) + EXVIERA® (DASABUVIR TABLETS) WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN GENOTYPE 1B:
http://hepatitiscnewdrugs.blogspot.com/2016/02/abbvie-receives-chmp-positive-opinion.html
This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir:
http://hepatitiscnewdrugs.blogspot.com/2016/02/elbasvirgrazoprevir-hcv-guidance.html
Why Americans pay so much more for drugs:
http://hepatitiscnewdrugs.blogspot.com/2016/02/why-america-pays-so-much-more-for-drugs.html
Quoted from the above article. Steve Miller, chief medical officer of Express Scripts wrote:
“The U.S. is 4.6 percent of the world’s population, we’re 32 percent of the world’s drug revenue, and we’re somewhere between 50 and 70 percent of world drug profitability,” Miller said. “The United States has been spending money to protect the world for decades. We’re now being asked to essentially fund all pharmaceutical drug development. … We cannot continue to carry this burden.”
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2429 February 2016 at 8:16 pm #12989Interesting…
http://hepatitiscnewdrugs.blogspot.com/2016/02/his-job-is-to-sell-1000-pill-for-10.html
RE; Australia:
http://hepatitiscnewdrugs.blogspot.com/2016/02/australia-hep-c-cures-now-as-cheap-as.html
Lack of awareness, affordability, etc.
http://hepatitiscnewdrugs.blogspot.com/2016/02/hepatitis-c-cure-now-affordable-but.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 244 March 2016 at 8:09 pm #13301Friday 3/4/2016
http://hepatitiscnewdrugs.blogspot.com/2016/03/watchdog-hepatitis-c-drugs-now-covered.html
http://hepatitiscnewdrugs.blogspot.com/2016/03/new-york-attorney-general-probes.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 247 March 2016 at 4:24 pm #13472The”Buyers’ Club Era” article, among others:
http://hepatitiscnewdrugs.blogspot.com/2016/03/march-heaptitis-newsletters-with-news.html?m=1
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 248 March 2016 at 10:27 pm #13538Recommendations from John W. Ward, MD, director of the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC).:
http://hepatitiscnewdrugs.blogspot.com/2016/03/cost-keeps-hcv-care-out-of-reach.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2410 March 2016 at 10:19 pm #13634From the CDC:
Annual Report to the Nation: Cancer death rates continue to declineIncrease in liver cancer deaths cause for concern
http://hepatitiscnewdrugs.blogspot.com/2016/03/cancer-death-rates-decline-but-increase.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2414 March 2016 at 5:08 am #13784Merck vs Gilead:
http://hepatitiscnewdrugs.blogspot.com/2016/03/a-tale-of-two-new-hepatitis-c-drugs.html?m=1Insurers rail against exorbitant drug costs:
http://hepatitiscnewdrugs.blogspot.com/2016/03/insurers-academics-protest-high-cost.html?m=1
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2417 March 2016 at 6:53 pm #14035Some good reading here in “HCV Next”
http://hepatitiscnewdrugs.blogspot.com/2016/03/hcv-next-narrowing-gap-impact-of.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2418 March 2016 at 7:33 pm #141293/18/16
http://hepatitiscnewdrugs.blogspot.com/2016/03/mar-2016-update-upcoming-and-recruiting.html
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2421 March 2016 at 6:39 pm #14340Why U.S. prices will stay high:
http://hepatitiscnewdrugs.blogspot.com/2016/03/no-clear-path-to-government-lowered.html?m=1
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 24 -
AuthorPosts
- You must be logged in to reply to this topic.